Brokers Offer Predictions for Krystal Biotech Q1 Earnings

Krystal Biotech, Inc. (NASDAQ:KRYS) – Stock analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Krystal Biotech in a note issued to investors on Wednesday, February 19th. HC Wainwright analyst J. Pantginis anticipates that the company will post earnings per share of $1.56 for the quarter. HC Wainwright has a “Buy” rating and a $221.00 price target on the stock. The consensus estimate for Krystal Biotech’s current full-year earnings is $6.14 per share. HC Wainwright also issued estimates for Krystal Biotech’s Q2 2025 earnings at $1.74 EPS, Q3 2025 earnings at $1.98 EPS, Q4 2025 earnings at $2.24 EPS, FY2025 earnings at $6.97 EPS, FY2026 earnings at $6.23 EPS, FY2027 earnings at $8.49 EPS and FY2028 earnings at $8.78 EPS.

KRYS has been the topic of a number of other reports. Citigroup lifted their price objective on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a research note on Thursday. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price objective on shares of Krystal Biotech in a research note on Thursday. Finally, Chardan Capital lifted their price objective on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a research note on Thursday. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $210.00.

Krystal Biotech Price Performance

Shares of NASDAQ:KRYS opened at $187.86 on Monday. The company’s fifty day moving average price is $157.85 and its 200 day moving average price is $175.26. Krystal Biotech has a 12 month low of $107.50 and a 12 month high of $219.34. The firm has a market capitalization of $5.41 billion, a P/E ratio of 62.83 and a beta of 0.84.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, February 24th. The company reported $1.52 EPS for the quarter, topping the consensus estimate of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The firm had revenue of $91.10 million for the quarter, compared to analyst estimates of $91.35 million. During the same period last year, the business earned $0.30 EPS. Krystal Biotech’s revenue for the quarter was up 116.4% compared to the same quarter last year.

Insider Transactions at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the transaction, the insider now directly owns 1,475,882 shares in the company, valued at $243,195,835.96. The trade was a 1.67 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 14.10% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Entropy Technologies LP acquired a new position in shares of Krystal Biotech during the fourth quarter worth about $548,000. Summit Trail Advisors LLC purchased a new stake in Krystal Biotech during the third quarter worth about $1,893,000. Swiss National Bank boosted its holdings in Krystal Biotech by 8.0% during the third quarter. Swiss National Bank now owns 39,100 shares of the company’s stock worth $7,117,000 after buying an additional 2,900 shares in the last quarter. Janney Montgomery Scott LLC boosted its holdings in Krystal Biotech by 42.0% during the fourth quarter. Janney Montgomery Scott LLC now owns 52,592 shares of the company’s stock worth $8,239,000 after buying an additional 15,545 shares in the last quarter. Finally, Citigroup Inc. boosted its holdings in Krystal Biotech by 65.4% during the third quarter. Citigroup Inc. now owns 35,084 shares of the company’s stock worth $6,386,000 after buying an additional 13,874 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors and hedge funds.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).